The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform
Matthew J Zirwas - One of the best experts on this subject based on the ideXlab platform.
-
warfarin induced venous limb Gangrene
The Journal of clinical and aesthetic dermatology, 2012Co-Authors: Sarah Grim Hostetler, Jennifer A Sopkovich, Steven M Dean, Matthew J ZirwasAbstract:Warfarin is a commonly used anticoagulant that has been associated with several significant cutaneous side effects, most notably warfarin-induced skin necrosis. A lesser known adverse reaction to warfarin is warfarin-induced venous limb Gangrene. Both cutaneous adverse effects share the same pathophysiology, but are clinically quite different. The majority of cases of warfarin-induced venous limb Gangrene has been in patients with cancer or heparin-induced thrombocytopenia. However, other hypercoagulable disease states, such as the antiphospholipid antibody syndrome, can be associated with venous limb Gangrene. In order to increase recognition of this important condition, the authors report a case of warfarin-induced venous limb Gangrene in a patient with presumed antiphospholipid antibody syndrome and review the literature on warfarin-induced venous limb Gangrene.
Saira Jan - One of the best experts on this subject based on the ideXlab platform.
-
fournier s Gangrene in patients with type 2 diabetes using second line antidiabetic medications
Diabetes Obesity and Metabolism, 2020Co-Authors: Natalia Petruskiivleva, Sebastian Schneeweiss, Sara Eapen, Aditya Rajan, Saira JanAbstract:Cases of a rare but serious infection called Fournier's Gangrene have been reported with sodium-glucose co-transporter-2 inhibitors (SGLT-2i). To evaluate the safety signal in a population of patients with type 2 diabetes, we used administrative claims data from Horizon Blue Cross Blue Shield of New Jersey from 2014 through 2017 to estimate incidence rates of Fournier's Gangrene or necrotizing fasciitis of the perineum among patients treated with a second-line antidiabetic drug. We found very low incidence rates of Fournier's Gangrene or necrotizing fasciitis. While we found no indication of an increased risk among SGLT-2i users compared with similar patients treated with other second-line antidiabetic medications, the small number of events yielded wide confidence intervals.
Benjamin J. Davies - One of the best experts on this subject based on the ideXlab platform.
-
Validation of the Fournier's Gangrene Severity Index in a Large Contemporary Series
The Journal of urology, 2008Co-Authors: Anthony T. Corcoran, Marc C. Smaldone, Erin P. Gibbons, Thomas J. Walsh, Benjamin J. DaviesAbstract:Purpose: In this study we identified prognostic factors for survival and validated the accuracy of the Fournier's Gangrene severity index in patients with Fournier's Gangrene.Materials and Methods: We retrospectively reviewed medical records of patients diagnosed with Fournier's Gangrene between 1996 and 2006. Fournier's Gangrene severity index scores were assessed using a receiver operating characteristic curve. Using an outcome variable of inpatient mortality, univariate analyses were performed using the Mann-Whitney U, chi-square and Fisher exact tests.Results: A total of 68 patients (79.4% male, mean age 55.8 ± 15.2 years) diagnosed with Fournier's Gangrene met the criteria for review. The inpatient mortality rate was 10% (7 patients). The mean Fournier's Gangrene severity index score for survivors was 5.4 ± 3.5 vs 10.9 ± 4.7 for nonsurvivors (p = 0.006). Isolated Fournier's Gangrene severity index and individual laboratory parameters associated with mortality included heart rate (p = 0.05), respirato...
Sarah Grim Hostetler - One of the best experts on this subject based on the ideXlab platform.
-
warfarin induced venous limb Gangrene
The Journal of clinical and aesthetic dermatology, 2012Co-Authors: Sarah Grim Hostetler, Jennifer A Sopkovich, Steven M Dean, Matthew J ZirwasAbstract:Warfarin is a commonly used anticoagulant that has been associated with several significant cutaneous side effects, most notably warfarin-induced skin necrosis. A lesser known adverse reaction to warfarin is warfarin-induced venous limb Gangrene. Both cutaneous adverse effects share the same pathophysiology, but are clinically quite different. The majority of cases of warfarin-induced venous limb Gangrene has been in patients with cancer or heparin-induced thrombocytopenia. However, other hypercoagulable disease states, such as the antiphospholipid antibody syndrome, can be associated with venous limb Gangrene. In order to increase recognition of this important condition, the authors report a case of warfarin-induced venous limb Gangrene in a patient with presumed antiphospholipid antibody syndrome and review the literature on warfarin-induced venous limb Gangrene.
Xiaofeng Zeng - One of the best experts on this subject based on the ideXlab platform.
-
prevalence risk factors and outcome of digital Gangrene in 2684 lupus patients
Lupus, 2009Co-Authors: A Liu, Wen Zhang, Xinping Tian, Xuan Zhang, Fengchun Zhang, Xiaofeng ZengAbstract:The aim of the study is to assess the clinical characteristics, risk factors and outcome of patients with systemic lupus erythematosus (SLE) complicated with digital Gangrene. In all, 2684 consecutive SLE inpatients admitted to Peking Union Medical College Hospital from December 1997 to August 2007 were studied. Demographic data, clinical features, laboratory findings as well as therapeutic regimens were systematically reviewed and a database was established. Cases with digital Gangrene were identified and followed up. 1) Eighteen patients with SLE were complicated with digital Gangrene, the average age at event was 33.1 +/- 11.8 years and the average disease duration was 99.1 +/- 60.1 months. 2) Patients with SLE, with long disease duration (> or =4 years), Raynaud's phenomenon and elevated serum C-reactive protein (CRP) were more likely to develop digital Gangrene, P = 0.006, 0.001, and 0.031, respectively, OR = 1.03 (95% CI 1.01, 1.04), 35.76 (95% CI 4.67, 273.83) and 9.93 (95% CI 1.23, 80.30), respectively. 3) Fifteen Gangrene patients started prednisone > or =1 mg/kg/d, and 18 were treated with cyclophosphamide, although 8 cases failed and ultimately received digital amputation. Prompt corticosteroid treatment (prednisone > or = mg/kg/d started within 3 weeks) decreased the hazard of amputation, P = 0.073, HR = 0.13 (95% CI 0.01, 1.21). Long disease duration, Raynaud's phenomenon and elevated serum CRP were independent predictive factors for SLE to develop digital Gangrene. Early and aggressive corticosteroid treatment prevented Gangrene from progression and improved prognosis.
